Genetic variation
3:g.38736063T>A
This variation affects:
Overview
3:g.38736063T>A is a genetic variant associated with Atrial fibrillation and Brugada syndrome.
This variant is located on chromosome 3. The variations at position 38736063 are the genetic letters T/T, G/T, A/T, C/T
Since humans have each twice (one from each parent), these letter-variations occur on both chromosomes. People can have the same or different letters on both chromosomes. Every person's individual variation assembly is referred to as genotype. For variant 3:g.38736063T>A there are 4 currently known genotypes : T/T, G/T, A/T or C/T
Short Overview
Variant Location
3:g.38736063T>A is located on gene in chromsome 3. Use the genome browser to explore the location of 3:g.38736063T>A and its genetic neighbourhood.
Conditions & Traits
3:g.38736063T>A affects the following conditions and traits:
Pharmacogenetics
3:g.38736063T>A affects the following drugs:
Diagnostics
3:g.38736063T>A is commonly tested together with other variants on the same gene.
Genome Browser
This interactive browser visualizes what no human can see with the naked eye - our DNA. From a down to a specific position on a . The position you are looking at here is the exact location of variant . Explore more variants and their effects on the body by browsing left and right along the DNA strand.
Did you know variants affect drugs?
Mutations are random changes in the DNA and genetic variations are differences in the DNA among people. Variants are tiny changes in just one piece of the DNA while haplotypes are groups of these changes that usually come together.
Dr. Wallerstorfer
Conditions & Traits of 3:g.38736063T>A
The different genotypes of variant 3:g.38736063T>A can affect the expression or likelyhood of developing certain traits or conditions. Current research shows that 2 conditions and 0 traits are associated with 3:g.38736063T>A. The following table shows the relationship between genotypes and conditions and traits.
Did you know variants affect drugs?
Variants can influence how our body reacts to certain drugs. The presence of specific variants can increase or decrease the efficiency and effectiveness of a drug, impacting how well it works inside our system. Additionally, certain variants can heighten or lessen the toxicity of a drug, thereby affecting the risk of unwanted side effects. They can also alter how a drug is metabolized, which influences the appropriate dosage one should receive.
Dr. Wallerstorfer
Variant Classification based on Scientific Studies
Scientific studies classifications aim to uncover how genetic variants function and their roles in diseases, traits, and evolution. Variants are categorized based on their functional impact, such as loss-of-function (reduces gene activity), gain-of-function (increases gene activity), neutral (no significant impact), or evolutionary conservation. This classification uses experimental data, population studies, and computational analyses to understand variant effects. Unlike clinical testing, which focuses on immediate health impacts, scientific studies explore broader genetic mechanisms and long-term implications.
Genotype
T
T
Level of evidence
No Effect
Unisex
0 Sources
Participants: 0
No available data
Genotype
G
T
Level of evidence
No Effect
Unisex
0 Sources
Participants: 0
No available data
Genotype
A
T
Level of evidence
No Effect
Unisex
0 Sources
Participants: 0
No available data
Genotype
C
T
Level of evidence
No Effect
Unisex
0 Sources
Participants: 0
No available data
Genotype
T
T
Level of evidence
No Effect
Unisex
0 Sources
Participants: 0
No available data
Genotype
G
T
Level of evidence
No Effect
Unisex
0 Sources
Participants: 0
No available data
Genotype
A
T
Level of evidence
No Effect
Unisex
0 Sources
Participants: 0
No available data
Genotype
C
T
Level of evidence
No Effect
Unisex
0 Sources
Participants: 0
No available data
Genotype
T
T
Level of evidence
Increased likelihood
Unisex
1 Sources
Participants: 586
The genotype with the letters T/T is considered a risk factor for developing the disease. Carriers of this genetic result are at increased risk of developing the disease.
Genotype
G
T
Level of evidence
Increased likelihood
Unisex
1 Sources
Participants: 586
The genotype with the letters G/T is considered a risk factor for developing the disease. Carriers of this genetic result are at increased risk of developing the disease.
Genotype
A
T
Level of evidence
Increased likelihood
Unisex
1 Sources
Participants: 586
The genotype with the letters A/T is considered a risk factor for developing the disease. Carriers of this genetic result are at increased risk of developing the disease.
Genotype
C
T
Level of evidence
Increased likelihood
Unisex
1 Sources
Participants: 586
The genotype with the letters C/T is considered a risk factor for developing the disease. Carriers of this genetic result are at increased risk of developing the disease.
Genotype
T
T
Level of evidence
Increased likelihood
Unisex
1 Sources
Participants: 586
The genotype with the letters T/T is considered a risk factor for developing the disease. Carriers of this genetic result are at increased risk of developing the disease.
Genotype
G
T
Level of evidence
Increased likelihood
Unisex
1 Sources
Participants: 586
The genotype with the letters G/T is considered a risk factor for developing the disease. Carriers of this genetic result are at increased risk of developing the disease.
Genotype
A
T
Level of evidence
Increased likelihood
Unisex
1 Sources
Participants: 586
The genotype with the letters A/T is considered a risk factor for developing the disease. Carriers of this genetic result are at increased risk of developing the disease.
Genotype
C
T
Level of evidence
Increased likelihood
Unisex
1 Sources
Participants: 586
The genotype with the letters C/T is considered a risk factor for developing the disease. Carriers of this genetic result are at increased risk of developing the disease.
Pharmacogenetics
The genetic variant 3:g.38736063T>A impacts how certain medications work in the body. This difference may cause some of us to require different dosage amounts to achieve the desired effects, while others might experience more apparent side-effects. As a result, healthcare providers may need to adjust prescriptions for those individuals with 3:g.38736063T>A. Ultimately, understanding our genetic makeup helps improve the overall effectiveness and usability of medications. Tailoring treatments based on genetics ensures a safer, more personalized healthcare experience.
Drugs related to 3:g.38736063T>A
All drugs that are linked to 3:g.38736063T>A are listed here.
Diagnostics
3:g.38736063T>A is commonly tested together with other variants on the same gene.
Related variants
Conditions and traits are often affected by more than one variant. It is important to understand these other factors to get a better understanding of how genetics affect certain conditions and traits. The following grid shows other variants that affect the same conditions and traits as 3:g.38736063T>A.
Genotype Distribution
Knowing your genome can actually tell you a lot about your ancestors.
The prevalence of the different genotypes is based on the native inhabitants of a region. In the map below you see how common each genotype is in the native inhabitants of those regions. Since genetic material is passed down form generation to generation, your DNA shows traces of the geographical origins of your ancestors.
This data is based on “The 1000 Genomes Project” which established one of the most detailed overviews of human genetic variations across the globe. The regions are broadly categorized into five continental groups: Africa, America, Europe, South Asia and East Asia. All continental groups together display the global prevalence. Click through the regions, to learn more about the local prevalence of the possible genotypes.
At present, there is no distribution data available for SNP 10428132. 10428132.
Studies and Sources
All of the resources below examine variant
Connie R Bezzina, Julien Barc, Yuka Mizusawa, Carol Ann Remme, Jean-Baptiste Gourraud, Floriane Simonet, Arie O Verkerk, Peter J Schwartz, Lia Crotti, Federica Dagradi, Pascale Guicheney, Véronique Fressart, Antoine Leenhardt, Charles Antzelevitch, Susan Bartkowiak, Martin Borggrefe, Rainer Schimpf, Eric Schulze-Bahr, Sven Zumhagen, Elijah R Behr, Rachel Bastiaenen, Jacob Tfelt-Hansen, Morten Salling Olesen, Stefan Kääb, Britt M Beckmann, Peter Weeke, Hiroshi Watanabe, Naoto Endo, Tohru Minamino, Minoru Horie, Seiko Ohno, Kanae Hasegawa, Naomasa Makita, Akihiko Nogami, Wataru Shimizu, Takeshi Aiba, Philippe Froguel, Beverley Balkau, Olivier Lantieri, Margherita Torchio, Cornelia Wiese, David Weber, Rianne Wolswinkel, Ruben Coronel, Bas J Boukens, Stéphane Bézieau, Eric Charpentier, Stéphanie Chatel, Aurore Despres, Françoise Gros, Florence Kyndt, Simon Lecointe, Pierre Lindenbaum, Vincent Portero, Jade Violleau, Manfred Gessler, Hanno L Tan, Dan M Roden, Vincent M Christoffels, Hervé Le Marec, Arthur A Wilde, Vincent Probst, Jean-Jacques Schott, Christian Dina, Richard Redon
Laura Andreasen, Jonas B Nielsen, Stine Darkner, Ingrid E Christophersen, Javad Jabbari, Lena Refsgaard, Jens J Thiis, Ahmad Sajadieh, Arnljot Tveit, Stig Haunsø, Jesper H Svendsen, Nicole Schmitt, Morten S Olesen
Yukiko Nakano, Hidenori Ochi, Yuko Onohara, Masaaki Toshishige, Takehito Tokuyama, Hiroya Matsumura, Hiroshi Kawazoe, Shunsuke Tomomori, Akinori Sairaku, Yoshikazu Watanabe, Hiroki Ikenaga, Chikaaki Motoda, Kazuyoshi Suenari, Yasufumi Hayashida, Daiki Miki, Nozomu Oda, Shinji Kishimoto, Noboru Oda, Yukihiko Yoshida, Satoshi Tashiro, Kazuaki Chayama, Yasuki Kihara